Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer

At the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, the Phase III AFU-GETUG-20 trial reported that adjuvant androgen deprivation therapy did not improve outcomes when added to surgery for patients with high-risk prostate cancer. Using 2 years of androgen deprivation therapy after radical prostatectomy in high-risk patients with undetectable postoperative PSA did not significantly improve metastasis-free survival. First author François Rozet, MD, a senior surgeon in the Department of Urology at the Institut Mutualiste.